Medco Warms Up To Part D: Plans "Creative" Role In Medicare Rx
This article was originally published in The Pink Sheet Daily
Executive Summary
The PBM is now "hopeful" that it can participate in the stand-alone Medicare drug insurance market after previously focusing on the "fallback" opportunity. Medco is working on a "creative and innovative solution" that will resolve its concerns about going at risk.
You may also be interested in...
PBMs Eye Acquisitions In “Target-Rich Environment”
Medco could limit cost of an acquisition to $300 mil. as the pharmacy benefit manager plans to have cash on hand to build its Medicare Rx business. Express Scripts says it is interested in acquisitions that would add scale to its PBM and specialty pharmacy businesses.
PBMs Eye Acquisitions In “Target-Rich Environment”
Medco could limit cost of an acquisition to $300 mil. as the pharmacy benefit manager plans to have cash on hand to build its Medicare Rx business. Express Scripts says it is interested in acquisitions that would add scale to its PBM and specialty pharmacy businesses.
“Fallback” Plan Will Be Main Medicare Rx Program, Medco Predicts
The private sector is unlikely to offer stand-alone drug insurance plans under Medicare in 2006, Medco CEO David Snow predicted during the Goldman Sachs conference in Laguna Niguel, Calif. June 9